# Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults

> **NCT03293732** · PHASE1 · COMPLETED · sponsor: **Advagene Biopharma Co. Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Flu, Human

## Interventions

- **BIOLOGICAL:** DCB07010
- **BIOLOGICAL:** HA antigens

## Key facts

- **NCT ID:** NCT03293732
- **Lead sponsor:** Advagene Biopharma Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-28
- **Primary completion:** 2013-03-30
- **Final completion:** 2013-09-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03293732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03293732, "Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03293732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*